SARS-CoV-2 serological results and total immunoglobulin levels by disease-modifying therapies
| No DMT | Anti-CD20 | Interferon beta | Glatiramer | Teriflunomide | Dimethyl-fumarate | Natalizumab | Fingolimod | Other* | |
| Number | 21 | 21 | 4 | 10 | 17 | 23 | 14 | 6 | 3 |
| Delay from COVID-19 (months), mean (SD) | 5.4 (3.7) | 4.2 (3.1) | 7.6 (2.7) | 5.4 (4.0) | 5.4 (3.6) | 5.3 (3.4) | 5.0 (3.5) | 3.4 (2.3) | 1.9 (0.2) |
| SARS-COV2 serology | |||||||||
| Anti-S IgG positivity, n (%) | 20 (95.2%) | 8 (38.1%) | 4 (100%) | 9 (90%) | 13 (76.5%) | 19 (82.6%) | 12 (92.8%) | 4 (66.7%) | 3 (100%) |
| Anti-S IgG title (log AU/mL), mean (SD) | 2.7 (0.8) | 1.4 (1.6) | 2.9 (0.9) | 2.5 (0.8) | 2.2 (1.1) | 2.3 (1.3) | 2.5 (1.1) | 2.1 (0.9) | 3.0 (0.3) |
| Anti-S IgA positivity, n (%) | 15 (71.4%) | 7 (33.3%) | 3 (75%) | 7 (70%) | 11 (64.7%) | 12 (52.2%) | 12 (85.7%) | 3 (50%) | 3 (100%) |
| Anti-S IgA index, mean (SD) | 2.4 (3.2) | 1.1 (0.5) | 1.8 (0.9) | 1.9 (1.5) | 1.5 (1.2) | 1.4 (0.8) | 2.1 (1.0) | 3.8 (6.5) | 2.2 (0.7) |
| Anti-N IgG positivity, n (%) | 17 (80.9%) | 3 (14.3%) | 2 (50%) | 8 (80%) | 11 (64.7%) | 18 (78.3%) | 10 (71.4%) | 4 (66.7%) | 3 (100%) |
| Anti-N IgG index, mean (SD) | 2.7 (2.5) | 0.5 (1.0) | 1.1 (1.0) | 3.2 (2.8) | 2.3 (2.8) | 2.3 (2.0) | 1.3 (1.2) | 2.0 (1.8) | 4.1 (2.3) |
| Total IgG (g/L), mean (SD) | 10.4 (2.7) | 9.1 (2.0) | 14.2 (2.1) | 12.4 (2.4) | 9.5 (2.3) | 10.7 (2.5) | 12.0 (2.7) | 9.0 (3.4) | 11.3 (2.3) |
| Total IgA (g/L), mean (SD) | 2.2 (0.8) | 1.9 (1.0) | 1.4 (0.4) | 2.6 (0.7) | 1.4 (0.7) | 1.9 (0.7) | 2.2 (0.9) | 1.5 (0.7) | 1.6 (0.9) |
| Total IgM (g/L), mean (SD) | 1.3 (0.8) | 0.8 (0.4) | 2.1 (1.9) | 1.7 (0.8) | 0.9 (0.5) | 1.2 (0.5) | 0.8 (0.9) | 0.9 (0.3) | 1.4 (1.1) |
For numerical variables, results are marked in bold when different (p<0.05) from other groups by ANOVA (for numerical dependent variables). Independent variable is ‘DMT group’ (9-level variable), and p values are calculated for a DMT group vs the intercept of the model.
For categorical variables (eg, Ig positivity), a Χ2 test was performed with the 9-level ‘DMT group’ as independent variable. For this group-level analysis, all p values were <0.05. Using a post-hoc Χ2 test, we found a significantly decreased positivity rate (marked in bold) for all Ig in anti-CD20 group vs pooled other DMT groups.
*Other treatments: methotrexate (n=1); azathioprine (n=1); mycophenolate mofetil (n=1).
ANOVA, analysis of variance; DMT, disease-modifying therapy.